ARTICLE | Company News
FDA approves Ibrance for men with breast cancer
April 19, 2019 5:22 PM UTC
Pfizer said FDA approved an sNDA for Ibrance palbociclib based on real-world data to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in men in combination with an aromatase inhibitor or fulvestrant.
Pfizer Inc. (NYSE:PFE) said the supporting data came from electronic health records and postmarketing reports sourced from three databases: IQVIA Insurance database, Flatiron Health Breast Cancer database and the Pfizer global safety database...
BCIQ Company Profiles